Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.

Journal Article

Full Text

Duke Authors

Cited Authors

  • Heimberger, AB; Archer, GE; McLendon, RE; Price, D; Friedman, AH; Friedman, HS; Bigner, DD; Sampson, JH

Published Date

  • November 2000

Published In

Volume / Issue

  • 6 /

Start / End Page

  • 4542S - 4543S

International Standard Serial Number (ISSN)

  • 1078-0432